Stonebridge Capital Management Inc. Has $6.53 Million Stake in Johnson & Johnson (NYSE:JNJ)

Stonebridge Capital Management Inc. grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.4% in the 1st quarter, HoldingsChannel.com reports. The fund owned 41,284 shares of the company’s stock after acquiring an additional 175 shares during the period. Johnson & Johnson accounts for about 2.9% of Stonebridge Capital Management Inc.’s investment portfolio, making the stock its 10th biggest holding. Stonebridge Capital Management Inc.’s holdings in Johnson & Johnson were worth $6,531,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Private Advisory Group LLC increased its position in shares of Johnson & Johnson by 11.8% during the third quarter. Private Advisory Group LLC now owns 2,576 shares of the company’s stock worth $401,000 after purchasing an additional 271 shares in the last quarter. Van Lanschot Kempen Investment Management N.V. grew its holdings in shares of Johnson & Johnson by 21.8% during the third quarter. Van Lanschot Kempen Investment Management N.V. now owns 496,621 shares of the company’s stock valued at $77,349,000 after buying an additional 88,912 shares during the last quarter. Nomura Holdings Inc. grew its holdings in shares of Johnson & Johnson by 39.3% during the third quarter. Nomura Holdings Inc. now owns 41,139 shares of the company’s stock valued at $6,407,000 after buying an additional 11,605 shares during the last quarter. Cape Cod Five Cents Savings Bank grew its holdings in shares of Johnson & Johnson by 98.1% during the third quarter. Cape Cod Five Cents Savings Bank now owns 160,604 shares of the company’s stock valued at $25,014,000 after buying an additional 79,543 shares during the last quarter. Finally, Ascent Group LLC boosted its holdings in Johnson & Johnson by 49.5% in the third quarter. Ascent Group LLC now owns 44,640 shares of the company’s stock valued at $6,581,000 after purchasing an additional 14,786 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.4 %

Shares of Johnson & Johnson stock traded down $0.62 during mid-day trading on Thursday, hitting $146.20. The stock had a trading volume of 1,031,975 shares, compared to its average volume of 7,356,585. The firm has a 50-day moving average of $148.13 and a two-hundred day moving average of $154.24. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The firm has a market cap of $351.86 billion, a P/E ratio of 9.14, a price-to-earnings-growth ratio of 2.45 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The firm had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter last year, the company posted $2.68 EPS. Sell-side analysts forecast that Johnson & Johnson will post 10.63 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were given a dividend of $1.24 per share. The ex-dividend date of this dividend was Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.39%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on JNJ shares. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price target for the company from $169.00 to $170.00 in a report on Thursday, April 18th. StockNews.com lowered shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 22nd. Morgan Stanley reduced their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 17th. The Goldman Sachs Group began coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They set a “neutral” rating and a $160.00 price target for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Thursday, June 20th. Eight investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $174.07.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.